SeaStar medical shares are trading higher after the FDA granted the company's Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome.
Portfolio Pulse from Benzinga Newsdesk
SeaStar Medical has received Breakthrough Device Designation from the FDA for its Selective Cytopheretic Device for hepatorenal syndrome. This has led to an increase in the company's stock price.
October 18, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SeaStar Medical's stock price has increased following the FDA's Breakthrough Device Designation for its hepatorenal syndrome device.
The FDA's Breakthrough Device Designation is a significant regulatory milestone that can lead to increased investor confidence and a rise in stock price. Given that the device is for hepatorenal syndrome, a condition with limited treatment options, this could potentially open up a significant market for SeaStar, further boosting its stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100